Q2
CABA — Q2 2026 Financial Report Analysis
Cabaletta Bio's Q2 2026 net loss widened 13% to $51.0M as R&D for its first registrational CAR T trial rose 18%; the per-share loss halved only because the share count more than doubled, and cash of $225.1M is guided to last into mid-2027, the same time myositis pivotal data are due.